SGLT-2抑制剂、GLP-1激动剂与DPP-4抑制剂对2型糖尿病患者全因死亡率的关联:系统综述与网络Meta分析
本研究通过系统综述与网络Meta分析,纳入236项随机临床试验、共176 310例2型糖尿病患者,比较SGLT-2抑制剂、GLP-1激动剂和DPP-4抑制剂对死亡及心血管终点的影响。结果显示SGLT-2抑制剂和GLP-1激动剂与较低的全因死亡率和心血管死亡率相关,而DPP-4抑制剂与对照组相比无显著差异。
要点
- SGLT-2抑制剂和GLP-1激动剂较DPP-4抑制剂或对照组降低全因死亡率。
- DPP-4抑制剂与对照组相比未显著降低全因死亡率。
- SGLT-2抑制剂还降低心衰事件和心肌梗死风险;GLP-1激动剂因不良事件停药风险较高。
核心结论
- SGLT-2抑制剂或GLP-1激动剂的使用与较DPP-4抑制剂或安慰剂/无治疗更低的全因死亡率相关。
- DPP-4抑制剂的使用与安慰剂/无治疗相比未显著降低全因死亡率。
研究设计与样本
- 系统综述与贝叶斯分层网络Meta分析,纳入236项随机临床试验,共176 310例2型糖尿病患者。
- 检索MEDLINE、Embase、Cochrane Library Central Register of Controlled Trials及已发表Meta分析,截至2017年10月11日。
- 纳入随访至少12周的随机临床试验,比较SGLT-2抑制剂、GLP-1激动剂或DPP-4抑制剂与彼此或安慰剂/无治疗。
主要发现
- SGLT-2抑制剂较对照组显著降低全因死亡率(绝对风险差-1.0%;HR 0.80 [95% CrI 0.71-0.89])。
- GLP-1激动剂较对照组显著降低全因死亡率(绝对风险差-0.6%;HR 0.88 [95% CrI 0.81-0.94])。
- SGLT-2抑制剂(HR 0.78 [95% CrI 0.68-0.90])和GLP-1激动剂(HR 0.86 [95% CrI 0.77-0.96])的全因死亡率低于DPP-4抑制剂。
- DPP-4抑制剂较对照组全因死亡率无显著差异(绝对风险差0.1%;HR 1.02 [95% CrI 0.94-1.11])。
- SGLT-2抑制剂较对照组显著降低心衰事件(HR 0.62 [95% CrI 0.54-0.72])和心肌梗死(HR 0.86 [95% CrI 0.77-0.97])风险。
关键数值与推荐
- 全因死亡率:SGLT-2抑制剂 vs 对照 HR 0.80(95% CrI 0.71-0.89);GLP-1激动剂 vs 对照 HR 0.88(95% CrI 0.81-0.94)。
- 全因死亡率:SGLT-2抑制剂 vs DPP-4抑制剂 HR 0.78(95% CrI 0.68-0.90);GLP-1激动剂 vs DPP-4抑制剂 HR 0.86(95% CrI 0.77-0.96)。
- 心血管死亡率:SGLT-2抑制剂 vs 对照 HR 0.79(95% CrI 0.69-0.91);GLP-1激动剂 vs 对照 HR 0.85(95% CrI 0.77-0.94)。
- 因不良事件导致试验退出的风险:GLP-1激动剂 vs SGLT-2抑制剂 HR 1.80(95% CrI 1.44-2.25);GLP-1激动剂 vs DPP-4抑制剂 HR 1.93(95% CrI 1.59-2.35)。
临床怎么用
- 在2型糖尿病降糖治疗选择中,SGLT-2抑制剂或GLP-1激动剂可能较DPP-4抑制剂或安慰剂/无治疗更有利于降低死亡风险。
- 对于关注心衰事件或心肌梗死风险的患者,SGLT-2抑制剂显示出额外获益。
- 选用GLP-1激动剂时需关注因不良事件导致停药的风险较高。
局限性
- 检索截止至2017年10月11日,未纳入此后发表的随机临床试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors for treatment of type 2 diabetes is unknown. OBJECTIVE: To compare the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using network meta-analysis. DATA SOURCES: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, and published meta-analyses from inception through October 11, 2017. STUDY SELECTION: Randomized clinical trials enrolling participants with type 2 diabetes and a follow-up of at least 12 weeks were included, for which SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors were compared with either each other or placebo or no treatment. DATA EXTRACTION AND SYNTHESIS: Data were screened by 1 investigator and extracted in duplicate by 2 investigators. A Bayesian hierarchical network meta-analysis was performed. MAIN OUTCOMES AND MEASURES: The primary outcome: all-cause mortality; secondary outcomes: cardiovascular (CV) mortality, heart failure (HF) events, myocardial infarction (MI), unstable angina, and stroke; safety end points: adverse events and hypoglycemia. RESULTS: This network meta-analysis of 236 trials randomizing 176 310 participants found SGLT-2 inhibitors (absolute risk difference [RD], -1.0%; hazard ratio [HR], 0.80 [95% credible interval {CrI}, 0.71 to 0.89]) and GLP-1 agonists (absolute RD, -0.6%; HR, 0.88 [95% CrI, 0.81 to 0.94]) were associated with significantly lower all-cause mortality than the control groups. SGLT-2 inhibitors (absolute RD, -0.9%; HR, 0.78 [95% CrI, 0.68 to 0.90]) and GLP-1 agonists (absolute RD, -0.5%; HR, 0.86 [95% CrI, 0.77 to 0.96]) were associated with lower mortality than were DPP-4 inhibitors. DPP-4 inhibitors were not significantly associated with lower all-cause mortality (absolute RD, 0.1%; HR, 1.02 [95% CrI, 0.94 to 1.11]) than were the control groups. SGLT-2 inhibitors (absolute RD, -0.8%; HR, 0.79 [95% CrI, 0.69 to 0.91]) and GLP-1 agonists (absolute RD, -0.5%; HR, 0.85 [95% CrI, 0.77 to 0.94]) were significantly associated with lower CV mortality than were the control groups. SGLT-2 inhibitors were significantly associated with lower rates of HF events (absolute RD, -1.1%; HR, 0.62 [95% CrI, 0.54 to 0.72]) and MI (absolute RD, -0.6%; HR, 0.86 [95% CrI, 0.77 to 0.97]) than were the control groups. GLP-1 agonists were associated with a higher risk of adverse events leading to trial withdrawal than were SGLT-2 inhibitors (absolute RD, 5.8%; HR, 1.80 [95% CrI, 1.44 to 2.25]) and DPP-4 inhibitors (absolute RD, 3.1%; HR, 1.93 [95% CrI, 1.59 to 2.35]). CONCLUSIONS AND RELEVANCE: In this network meta-analysis, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with lower mortality than DPP-4 inhibitors or placebo or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.
引用
- Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29677303. doi:10.1001/jama.2018.3024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。